

KERYX BIOPHARMACEUTICALS INC  
Form 8-K  
April 23, 2012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **April 23, 2012**

**Keryx Biopharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**

**000-30929**

**13-4087132**

(State or Other Jurisdiction (Commission File Number)

(IRS Employer Identification No.)

of Incorporation)

**750 Lexington Avenue**

**New York, New York 10022**

(Address of Principal Executive Offices)

**(212) 531-5965**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act.
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

**Item 8.01. Other Events**

On April 23, 2012, Keryx Biopharmaceuticals, Inc. (the “Company”) issued a press release announcing that its Japanese partner, Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co., Ltd. (Torii), announced positive top-line results from a Phase 3 study of ferric citrate in Japan for the treatment of hyperphosphatemia in end-stage renal disease patients on hemodialysis. A copy of such press release is furnished as Exhibit 99.1 to this report.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Keryx Biopharmaceuticals,  
Inc.  
(Registrant)

Date: April 23, 2012

By:/s/ James F. Oliviero  
James F. Oliviero  
Chief Financial Officer

INDEX TO EXHIBITS

Exhibit Number	Description
-------------------	-------------

99.1	Press Release dated April 23, 2012.
------	-------------------------------------